20 Aug Liquid Biopsy Biomarkers May Soon Detect Aggressive Brain Cancer

MedicalResearch.com Interview with:

Prof. Georgios Giamas

Georgios Giamas, (Dr. Biol. Hum.)
Professor of Cancer Cell Signalling
Director of Research and Knowledge Exchange
University of Sussex -School of Life Sciences
Visiting Professor, Imperial College, London

MedicalResearch.com: What is the background for this study?

Response: This study focuses on Glioblastoma (GBM), which is one of the most aggressive solid tumours for which treatment options and biomarkers are limited.

MedicalResearch.com: What are the main findings?

– Glioblastoma cells produce nanosized vesicles (aka: extracellular vesicles) that contain specific protein signatures, which can indicate the behaviour and phenotype of the respective cells of origin.

-We have identified and described certain vesicle-associated biomarkers that correspond to the most aggressive brain cancers.

-Our results can provide insights for the development of new diagnostic and therapeutic methods as well as personalized treatment strategies

MedicalResearch.com: What should readers take away from your report? 

Response: Specific protein biomarkers for highly aggressive subtypes of brain cancers can be described inside extracellular vesicles.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: Our current study provides inputs for future liquid biopsy applications and better patient follow-up care, as the expression levels of vesicle-associated biomarkers associated with the most aggressive cancers can increase upon tumour recurrence.

MedicalResearch.com: Is there anything else you would like to add?

Response: These data can be used by other scientists working in similar research fields in order to further elucidate the role of extracellular vesicles produced by brain cancer cells. Moreover, additional future ‘translational’ / clinical studies are needed to investigate and validate these newly identified biomarkers in glioblastoma patients.

No disclosures.

Citation:

Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping

Rosemary Lane, Thomas Simon, Marian Vintu, Benjamin Solkin, Barbara Koch, Nicolas Stewart,Graeme Benstead-Hume, Frances M. G. Pearl, Giles Critchley, Justin Stebbing & Georgios Giamas

Communications Biology volume 2, Article number: 315 (2019)

Last Modified: [last-modified]

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on August 20, 2019 by Marie Benz MD FAAD